Cellectar Biosciences Provides Strategic Update

 Evaluating strategic options for iopofosine I 131 a late-stage clinical program with compelling Phase 2 data and a substantial market opportunity

Focusing on advancing radiotherapeutic assets including alpha- and Auger-emitting radioconjugates into Phase 1 solid tumor studies

https://www.globenewswire.com/news-release/2024/12/10/2994986/29076/en/Cellectar-Biosciences-Provides-Strategic-Update-on-Clinical-Development-Pipeline-Programs-and-Corporate-Restructuring.html